To discuss the physiological basis of insulin treatment and its associated clinical aspects seems appropriate considering that insulin replacement in Type 1 (insulindependent) diabetes will be the more successful the closer it mimicks physiological insulin release. The final goal of any such approach is to re-establish the lost constancy of the metabolic 'milieu interieur' as the condition of a free and independent existence [1] . This common biological necessity, which had been recognized by Claude Bernard more than 40 years before the discovery of insulin, may very well also be applied to insulin replacement in Type I diabetes.
In spite of the long time elapsed since that statement, physiologic knowledge on the prerequisites for maintenance of a 'normoglycaemic milieu interieur' is, however, even today not commonplace to the attending physician, although treatment by insulin of Type I diabetes has been common procedure for more than 60 years. The reason for this apparent imbalance is, besides the fact that not all details on the regulation of insulin release and action have been worked out, that such essential physiologic background knowledge, which has become increasingly sophisticated over the last two decades, is rarely taught in detail to physicians. In addition, there is some lack of agreement as to what and how much is to be learned by Type 1 diabetic patients, whose B cells are progressively destroyed by a chronic autoimmune process [2] . The associated loss of the predominantly anabolic actions of insulin on muscle, liver and adipose tissues is devastating to the organism, since insulin is the only anabolic hormone acting ubiquitously. Thus, insulin promotes in healthy man protein synthesis as well as glucose uptake by extrahepatic tissues, primarily muscle, while simultaneously curbing hepatic glucose production, glycogenolysis and gluconeogenesis [3, 4] . Such insulin action is mediated by interaction with its receptor on the cell surface [5] , and subsequent internalization [6] and translocation in-* 18th Claude Bernard Lecture of the European Association for the Study of Diabetes delivered in Rome, Italy, 20 September 1986 to various intracellular organelles, including lysosomes and the Golgi apparatus [7] , as well as by cation flux [8] and phosphorylation-dephosphorylation cycles [8, 9] . All these effects depend heavily on insulin's highly selective action on the mitochondrial Krebs cycle, which is stimulated by insulin up to 30% [10] . Most importantly, absence of insulin action does not only derange substrate fluxes, but also leads to a shift of the dose-response curve of glucose vs. glucose utilization to the right, which signals extremely poor efficacy of glucose metabolism at normal blood glucose concentration [11] . This effect is accompanied secondarily by resistance to exogenous insulin action not only with regard to glucose, but also to lipid and amino acid metabolism [12] . Such insulin resistance has even been observed in states of protein-calorie malnutrition, where insulin secretory response is severely reduced [13] .
If we accept Claude Bernard's conceptualization that constancy of the 'milieu interieur' is required for a free and independent existence, then it becomes obvious that any form of insulin treatment has to be subject to considerable failure unless attempts are made to reinstitute in the insulin deficient organism a physiologic pattern of insulin availability.
With this in mind, I shall discuss in this overview: first, the efficacy of commonly employed insulin treatment; and second, the physiologic background of insulin replacement. I shall not comment on insulin pharmacokinetics or on therapeutical pancreas transplantation [14] and immunomodulation [15] , which in part both try to interfere with the disease process itself.
Outcome of conventional insulin treatment
Evaluating the outcome of conventional insulin treatment, which with its fixed insulin dosage and food intake has dominated the field for almost 65 years, it becomes apparent that it has reduced sharply the mortality of diabetic coma [16] , but not the occurrence of late diabetic complications, diabetic retinopathy in particular.
The latter finding recently has been reconfirmed in a cross-sectional survey of both metropolitan and rural Type I diabetic patients, who demonstrated a frightening prevalence of all forms of late diabetic complications amounting up to 41% for diabetic retinopathy, 25% for diabetic neuropathy and 15% for diabetic nephropathy with gross proteinuria [17] . No difference was seen in that outcome of conventional diabetes care as offered either by a diabetes center or by rural physicians, although normal HbAto values were seen more frequently in metropolitan (20.7%) than in rural (4.1%) Type 1 diabetic patients.
Against this background, which is in line with data provided earlier by K.West [18] and the Wisconsin study [19] , it appears legitimate to ask the following questions:
1. Is there anything currently wrong with insulin administration with one, two or even three injections of insulin per day, a procedure which now has been tested empirically for about 60 years? 2. Does the employed strategy of conventional insulin treatment per se, i.e. of insulin up to t. i.d. plus a fixed diet, hold any promise for further improvement of the metabolic and clinical lot of patients ? 3. Are there other ways of insulin substitution, and if so, what is their potential?
Physiological background of insulin treatment
The best way to approach an answer seems first to evaluate the normal 'dynamic milieu interieur' of insulin release in healthy man, and second to comment on appropriate and implementable alternate methods of insulin substitution. Any such evaluation from a clinical point of view, which always aims at therapeutically applicable consequences, has to deal with (a) the physiology of insulin release; (b) hepatic glucose disposal; (c) peripheral glucose disposal; (d) modulation of insulin action and release; and (e) the predicability of the induced modulation. In discussing some of these points I will be selective and by no means all-inclusive, but nevertheless I shall try to raise some important issues based on my own work as well as that of others.
Insulin release

The site
Insulin is released by the B cells, which are embedded in the islets of Langerhans and thus neighbour other cells which either secrete glucagon, somatostatin or pancreatic polypeptide. The B cells synthetize proinsulin and release insulin by exocytosis upon substrate triggered request through fenestrated endothelia and a delicate diaphragm in the capillary vasculature [20] . There, as well as within the islet parenchyma, nerve fibers are embedded. Contacts have been described between A-, B-and D-cells as tight and gap junctions. In addition, B cells are uniquely distributed, as they cover the central region of an islet and are surrounded by a peripheral rim of either glucagon or pancreatic polypeptide containing cells depending on the islets' intrapancreatic location [21, 22] , thereby forming a biosociological interdependent pattern.
Qualitative factors
Adequate stimuli triggering insulin release in healthy man are, besides glucose, amino acids and proteins [23, 24] . In ruminants, fatty acids are added to this list of Bcytotropic substrates [25] . The complexity of endocrine response to ingestion of a given substrate is best described after an oral glucose load, which stimulates splanchnic output of insulin, C-peptide, and transiently also that of pancreatic polypeptide [26] , while release of glucagon and growth hormone [27] is suppressed. These changes are accompanied by an early rise in plasma norepinephrine and a late increase in plasma epinephrine concentration [27] . In parallel, insulin secretion may be modulated by a variety of stimulatory and inhibitory factors. These include, as stimulators of insulin secretion, increased vagal activity as well as gastrointestinal, pancreatic, adrenal and hypophyseal hormones, while insulin itself [28] , proinsulin at pharmacologic concentration [29] , somatostatin [30, 31] and alpha-adrenergic agonists [32] act as inhibitors. This fine tuning of postprandial insulin release controls the associated blood glucose response best defined by concentrations of < 8.9 mmol/1 at 60 min, < 7.8 mmol/1 at 90 rain and < 6.7 mmol/1 at 120 min following a 100 g oral glucose load [33] . Copying even only part of such intricate control mechanisms wilt be utterly impossible for the clinician.
Pulsatility of insulin availability
Physiologically, insulin, C-peptide and glucagon are released in man [34, 35] and dog [36] in a pulsatile fashion, with a periodicity ranging from 8-30 min, with the frequency of pulses and the sum of amplitudes in insulin concentration determining overall insulin availability. This periodicity is well correlated with glucose induced oscillations of electrical activity in pancreatic islets [37] , but appears to be more episodic than cyclical if measured basally and during arginine administration in a hepatic vein [36] (Fig. 1) . The induced insulin concentration in peripheral venous or arterial serum in the postabsorptive (fasting) state ranges from 73-146pmol/1 (10-20 mU/1), while portal concentration is three times as high. Apparent half-life of free insulin has been reported to be in the order of 5.2 __+ 0.7 min, and may be increased in diabetic patients with high insulin antibody titres [38] . In vitro [39] , employing the isolated perfused rat liver as well as in vivo [40, 41] , pulsatile insulin exposure has been demonstrated to be equipotent in controlling hepatic glucose production to continuous exposure to the same hormone concentration, even though the absolute hormone load was reduced by 40% [41] to 66% [39] . This greater efficacy of pulsatile insulin exposure in suppressing hepatic glucose production is accompanied in Type 1 diabetic patients by an equipotent effect on glucose utilization [41] . Application of pulsatile insulin administration thus may benefit Type 1 diabetic patients by reducing both their constantly elevated free insulin levels [38] and insulin resistance by reversing down regulation of insulin receptors.
Hepatic insulin extraction
Drainage of insulin released by the B cell is via the portal vein and the liver bed, which clears about 50% [26, 42] of a given insulin load. Associated fractional hepatic insulin extraction, though constant during exogenous insulin administration [28] , may fall transiently during glucose ingestion [26, 43] . The physiological role of hepatic insulin clearance, which very well might be nonspecific, as the liver traps almost anything from gold to microaggregated albumin [44] , is to curb glucagon dependent glycogenolysis following carbohydrate ingestion [45] . In addition, insulin is cleared by kidneys [46] and to a quantitatively lesser extent by peripheral target cells after internalization of the insulin receptor complex [47] .
Furthermore, feedback inhibition by insulin [28] and proinsulin [29] of basal, but not of stimulated [48] insulin release may help to fine tune insulin secretion at low production rates. This feature would be hard to mimick during exogenous insulin administration.
Quantitation of insulin release
Healthy volunteers have been described to release in the basal state 14-17 mU insulin per rain [26, 49] or approx. 1 U/h, and following different oral glucose loads (12 to 100 g) ( Fig. 2) , about 0.9 U/150 rain and 10 g of ingested glucose, with the size of the glucose load being an important determinant of insulin response [26, 49, 50] . These calculations could be made on the basis of splanchnic C-peptide output, since C-peptide is released by the B cell equimolarily to insulin [51] and is not retained by the liver bed [52] . Thus, it has been shown that insulin release responds to glucose ingestion in a dose-dependent manner. A similar insulin release of 0.72 U/10 g glucose has been obtained by others [43] using kinetic analysis of peripheral plasma insulin concentration after stimulation of endogenous insulin release.
If corrected for incomplete absorption from the gut, which requires up to 210 rain and more [53] , an insulin release of approximately 1.35 U/12 g glucose may be a fair estimate [26, 49, 54] . Since there is no alternative to dose response curves for characterizing B-cell responsiveness to food ingestion, such data may be used as an estimate for minimal insulin requirement in patients completely devoid of endogenous insulin. It is important to emphasize that, under physiological conditions, fasting and prandial insulin replacement are to be viewed as separate and independent entities.
Hepatic glucose disposal
Normal blood glucose level in postabsorptive, 16-h fasting man is maintained by hepatic glucose production from glycogenolysis and gluconeogenesis totalling approximately lltxmol (=2mg).kg-l.min -1 [49, 55] . Contribution of gluconeogenic precursors to splanchnic glucose production in the postabsorptive state has been calculated to range up to 29% [56] . Following oral glucose loading a rapid rise in arterial concentration as well as splanchnic output is seen of glucose, pyruvate and lactate, which is paralleled by a fall in splanchnic FFA-uptake, and in splanchnic output of fl-hydoxybutyrate and acetoacetate [26, 49, 57] . It is also of note that the liver switches from net lactate uptake, when 12-25 g is ingested, to net production as the glucose load increases over 50 g [58] . These effects are accompanied by a mean 50% suppression of endogenous glucose production [55] while the remainder contributes to net splanchnic glucose release as measured by the hepatic venous catheter technique. Thus, any postprandial rise in splanchnic glucose output is primarily due to glucose absorbed from the gut and passing through the liver bed, while only a 10-30% share of ingested glucose is retained by the liver [26, 53, 55] if splanchnic glucose retention is calculated by a tracer technique [53, 55] (Fig.3) .
Conversely, splanchnic glucose retention was overestimated when only the hepatic venous catheter technique was employed [49, 57] . Hepatic glucose production may, however, also be reduced, e. g. by inhibition of gluconeogenesis due to ethanol exposure and alteration of the hepatic redox state [59] . This effect is accompanied in healthy man by a decrease in glucose utilization and resistance to insulin action by peripheral tissues [601. tion [10] . Plasma glucose may, however, also be cleared by non-oxidative glucose storage, which is virtually absent at a glucose uptake rate of 12 ~tmol (=2.2 rag). kg fat free mass -~. rain -1, but rises to 45% of glucose disposal at glucose uptake rates exceeding 39~mol (= 7 rag). kg fat free mass-a, rain-1 [65] . Peripheral glucose disposal and clearance, however, are blocked in part during and after a prolonged hypoglycaemic period [66] .
Peripheral glucose disposal
Extrahepatic tissue utilizes in the fasting state an identical amount of glucose as is provided by hepatic glucose production (11 ~tmol (= 2 mg). kg-i. min-1), a metabolic balance which is of tantamount importance in maintaining euglycaem~a. Following glucose ingestion it has been extrapolated that more than 40% and up to 70%-80% [61, 62] of ingested glucose are available to non-hepatic peripheral tissue. These data have also been obtained by evaluation of glucose uptake across the forearm [63] and the leg [61] , and were confirmed employing a double tracer technique in combination with hepatic venous catheterization [55] . Ingesting varying glucose loads it has been shown [49] that the suprabasal amount of glucose escaping the splanchnic bed in percent of ingested glucose is greater when smaller, but reduced when larger amounts of glucose are administered. Measuring glucose oxidation in normal man by continuous indirect calorimetry after glucose ingestion, 18% have been shown to be subject to suprabasal oxidation [64] , which supports Bessman's observation on a direct action of insulin on rnitochondrial substrate oxidaExercise During moderate exercise in the fasting state increased glucose utilization by muscle is closely matched by augmented hepatic glucose output, so that blood glucose concentration is kept constant [67] . Postexercise hypoglycaemia, which first had been observed by Lawrence [68] , is linked to increased glycogenolysis due to the exercise associated rise in glucagon, epinephrine and/or norepinephrine [69, 70] . The proposed autoregulation by the liver in response to a transient fall in blood glucose concentration has not been confirmed in more recent studies [70] . During prolonged exercise the main reason for matched control of hepatic glucose production and glucose utilization, however, resides in gluconeogenesis from 3-carbon compounds such as lactate, pyruvate and alanine provided by working muscle. In addition, exogenous oral glucose is effective as an energy supplying substrate during exercise [71] , while lack of exercise leaves that amount of adminstered glucose to other metabolic pathways and thus may even impair carbohydrate tolerance. Synergistic interaction between exercise and insulin on muscle glucose uptake [72] and the time-dependence of these effects [73] has been demonstrated. In man, exercise induced glycogen depletion produces an increase in glucose storage and insulin stimulated glucose disposal [74] , both of which may add to post-exercise hypoglycaemia in Type 1 diabetes and are associated with increased peripheral sensitivity to insulin [75] . This physiological background makes it necessary to reduce otherwise appropriate insulin replacement during and after physical exercise to avoid overutilization of glucose and to permit, at least to some extent, more marked gluconeogenesis. Thus, main determinants of glucose tolerance and of the rate of appearance of glucose after its ingestion are suppression of hepatic glucose production, a rise in peripheral glucose uptake, particularly by muscle, and splanchnic glucose clearance.
Modulation of insulin action and release
Stress hormones
A key role among modulators of insulin action is played by stress hormones, which serve to adapt the body to stresses ranging from mildly physiological to the intensely physical by affecting glucose supply as well as its utilization. These insulin counteracting (diabetogenic) hormones include catecholamines [76] , cortisol [77] , growth hormone [78] and glucagon [77] , all of which are known to increase glucose production, to cause an insulin resistant state and to raise in part splanchnic plasma flow. Among these hormones epinephrine followed by cortisol are most potent in inducing peripheral and hepatic insulin resistance in healthy man [79] and Type 1 diabetic patients [80] , where growth hormone and glucagon in descending order of magnitude are less diabetogenic in the presence of sufficient insulin supply [81] .
Specifically, elevating plasma concentrations of epinephrine and cortisol into the pathophysiologic range commonly seen during diabetic ketoacidosis [82] glucose tolerance was more markedly impaired during epinephrine than following cortisol infusion in healthy man [79] . Such action on carbohydrate metabolism by cortisol and epinephrine is associated with a 25% to 40% reduction in glucose clearance [77, 83] both in healthy subjects and in diabetic patients. Since epinephrine and cortisol administration are associated with an almost identical postprandial splanchnic glucose output (SGO) after ingestion of an identical oral glucose load, excess hyperglycaemia following epinephrine has to be due at least in part to impaired peripheral glucose clearance. A major difference in the behaviour of both stress hormones seems, however, also to reside in their impact on insulin secretion, which was inappropriately low for the induced glycaemia during epinephrine, but high during cortisol infusion. This finding is most likely due to alpha adrenergic inhibitory action of epinephrine on insulin secretion [32] . In addition, impairment by epinephrine of extrahepatic glucose utilization seems to contribute to the accompanying hyperglycaemia as suggested already by Cori and Coil [84] and others [85] , who observed reduction by epinephrine of insulin induced glucose clearance. The predominant clinical importance of stress hormone action has also been shown by the failure of pancreatectomy to induce hyperglycaemia in adrenalectomized and hypophysectomized dogs as demonstrated by Houssay and Penhos [861.
Osmolality
Besides stress hormones plasma hyperosmolality has been identified as a major factor in the development of insulin resistance both in diabetic patients [82] , and in healthy man after intravenous mannitol [87] and in vitro [88] , where reduced glucose uptake by fat tissue (Fig. 4) and muscle tissue was demonstrated during hyperosmolar perifusion [88] . Conversely, hyposmolal rehydration fluid without added insulin has been shown to successfully reduce blood glucose concentration in diabetic coma up to 2 mmol/h, besides decreasing plasma stress hormone concentration [82] (Fig. 5) .
Dawn phenomenon
The terminology of this event is confusing since the sequence from the nocturnal nadir of glycaemia to prebreakfast hyperglycaemia, i.e. the fasting ascending segment of glucose excursion (FAGE), recently has 
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Duration of food withdrawal (hi Fig.6 . Impairment of early morning ('Dawn'-) and evening ('Dusk'-phenomenon) glucose utilization ('M'; means _+ SD) by prolonged fasting in healthy man (n = 8). Blood glucose was clamped by variable glucose infusion at+8.9mmmol/1 (+125mg/dl) as described previously (97) .
been renamed the 'dawn phenomenon' [89] . Such early morning hyperglycaemia may occur subsequently to nocturnal hypoglycaemia [90, 91] and then is referred to as °posthypoglycaemic hyperglycaemia' [92] or 'Somogyi effect' [90] . This effect has both been attributed to interference by counterregulatory hormones subsequently to [90] or even independently from nocturnal hypoglycaemia [93] [94] [95] , to intrinsic 'brittleness' [93, 94] and to lack of insulin [90, 96] . Additional causes of early morning hyperglycaemia may, however, simply reside in tissue insensitivity to insulin action and in the size of the hepatic glycogen pool responding to a glycogenolytic stimulus. Such studies (Fig. 6 ), which just have been completed in my laboratory, demonstrated that glucose utilization during a + 6.9 retool/1 (= 125 mg/dl) hyperglycaemic clamp [97] at 08 : 00 hours in healthy man depended on the duration of food withdrawal and thus was smaller after a 14-h ('M'=32+4btmol-kg -1 rain-1) than after a 5-h fast ('M' = 47 _+ 6 umol. kg. rain; 2p < 0.01). This kind of 'dawn phenomenon' could easily be transformed into a 'dusk phenomenon' if the subjects were fasted throughout the day and clamped at + 6.9 mmol/1 at 20.00 hours. In this case a 14-h fast from 06.00 to 20.00 hours impaired evening glucose utilization from 35__+ 5 (after a 5-h fast) to 26+_3 ,ttmol. kg -1 -rain -1 (2p <0.05). This metabolic behaviour, which was obtained at identical basal insulin concentrations (49 + 7 vs 46 + 2 (SEM) pmol/1), demonstrates that insulin efficacy is the product of serum insulin concentration and insulin sensitivity of target tissues, and is in line with the demonstration in normal man of a 'dawn phenomenon' [98] , which is devoid of any prebreakfast rise in serum insulin concentration [99] . A further important determinant of blood glucose response to a given stimulus is the amount of available hepatic glycogen. Thus, a liver full of glycogen will release more glucose upon a given glycogenolytic stimulus than one less repleted with glycogen [100] . Thus, prebreakfast (postabsorptive) hepatic glucose production (mean+SD) was demonstrated to be 33% greater (21 + 4 btmol, kg-1. rain-1) in Type i diabetic patients fed the preceding day a hypercaloric diet (50 kcal/kg body weight) than in 36-h fasted patients (16+ 3 .ttmol/kg. rain). Furthermore, glycogenolytic action of intravenous glucagon (6 ng/kg, rain) was increased versus fasted diabetic patients by 32% following hypercaloric nutrition (unpublished observations).
From these data we have to conclude that early morning hyperglycaemia is a 'secondary phenomenon', which reflects a physiologic response to a given situation that depends on a subject's actual insulin sensitivity, the size of the hepatic glycogen pool, lack of insulin and on the availability of glycogenolytic and/or gluconeogenic counterregulatory hormones, as in their absence no hyperglycaemia may occur [90, 101, 102] .
In order to maintain all mentioned factors constant in a clinical setting would require one to permanently keep track of stress factors, of the patients' osmolal state and the actual insulin exposure, duration and concentration included. However, only the amount of insulin and fluid intake will be able to be controlled.
Predicability of glycaemic response
Being aware of the interplay between food ingestion, insulin release, hepatic glucose production as well as oxidation and storage of glucose by peripheral tissues, the question arises whether there is any predicability in blood glucose response to a given stimulus, e.g. stress hormone exposure in the absence of endogenous insu- lin, or if everything has to be 'brittle'. To this end healthy subjects were infused [103, 104] both with somatostatin to suppress endogenous insulin release and with a constant mixture of stress hormones sufficient to raise hormone levels to values seen in diabetic ketoacidosis [82] . To analyze the induced blood glucose response both curve and concept fitting techniques were used for computer modeling [105, 106, 107] , and to find an appropriate algorithm of sufficient predicative power. To design such an algorithm for blood glucose response to stress hormone action the time course, slope and amplitude of blood glucose response were determined. Appropriate experiments performed in healthy man demonstrated that absence of insulin for 36 h was unable to precipitate hyperglycaemia, which only occurred either immediately after epinephrine and glucagon, or with a 8-12h delay following cortisol and growth hormone administration. Such behaviour is in line with the hypothesis of the biphasic nature of the metabolic sequelae of stress, which are initiated by a rapidly acting catecholamine phase and perpetuated by a steroid peptide phase, i. e. by cortisol and growth hormone action [108] . The extent of blood glucose response to a second stress hormone stimulus depended both on its timing and on actual blood glucose concentration, and was greater if applied during the ascending than during the descending response to the first stimulus. The algorithm developed from the induced changes in blood glucose decomposes the metabolic system into two subprocesses, one of which describes the messenger and the other the glucose compartment (Fig. 7) .
Using this model for planning experiments with repetitive hormone exposure it became apparent that the developed algorithm was able to predict blood glucose response to repetitive stress hormone exposure in healthy postabsorptive subjects [103, 104] (Fig. 8) . These findings emphasize that at least stress hormone action is predictable in a defined metabolic setting of artefactual insulin deficiency. Conversely, it appears feasible that metabolic instability of the diabetic patient, which often is referred to as 'brittle diabetes', just reflects metabolic imbalance caused by too frequent uncontrolled intermittent exposure to hyperglycaemic and hypoglycaemic stimuli, i. e. to stress hormones, insulin and exercise, re-spectively. The regularity of blood glucose response to exogenous glycogenolytic and gluconeogenic stimuli let me, however, conclude that any brittleness of Type 1 diabetes must be caused by artefactual exogenous interference with a feedback system, which is destabilized by absence of fine tuned anabolic insulin action.
Treatment of Type 1 diabetes
If we try to sum up the basic facts of carbohydrate metabolism it becomes obvious that we are dealing with a beautifully controlled system, which by no means is 'brittle'. Its regulation is subject to a multitude of factors which include (I) the amount of glucose offered to the intestinal tract; (II) the percentage retained by the splanchnic area, liver in particular; the degree of associated suppression of hepatic glucose production, i. e. of hepatic glycogenolysis and gluconeogenesis; (III) the amount of glucose taken up and oxidized by peripheral, extrahepatic tissues, all of which depend on (IV) the response of insulin release to changes in blood substrate concentration, glucose and amino acids included as well as to modulation by stress hormones and exercise.
What the physician needs to do is select clinically applicable knowledge for symptomatic treatment of an insulin deficient state as it exists in Type 1 diabetes. This has been attempted in the past by what we would call today a fixed algorithm with a fixed diet linked to a prescribed insulin dosage. This conventional insulin therapy has saved many lives by sharply reducing the incidence of diabetic coma, but was commonly only able to stabilize mean blood glucose at about 11.7 mmol/1 [17, 18, 109] . This was the maximum that could be achieved without blood glucose self-control, which only became available [110] some 50 years after the discovery of insulin [111] . The failure of conventional insulin treatment to consistently maintain normal blood glucose values is due to not considering the physiologic pattern of insulin release, and to assuming constancy of food intake, physical activity, daily stress and insulin pharmacokinetics in Type I diabetic patients.
Functional insulin substitution
To design a more appropriate strategy for the treatment of Type 1 diabetes and to aim at near-normoglycaemia, advantage has to be taken mainly both of what has been learned about insulin release and of blood glucose selfcontrol, the latter permitting immediate action by the patient if blood glucose is off a given target. In addition, to motivate our patients' cooperation their requests are to be respected, which include subjective well-being, flexibility of food intake, simple rules for treatment and normoglycaemia. Therefore, any information offered to an insulin-deficient patient has to focus on what realistically can be transferred into practical use. With the tools at our disposal this will not be secondary stabiliza- tion of counterregulatory hormone action by drugs, but rather the design of a more flexible algorithm of insulin replacement than that provided by conventional insulin therapy.
To this end, and to permit more functional insulin replacement, basal and prandial insulin requirements have to be regarded as separate entities [54, 112] . This is important, since basal insulin substitution provides the basis on which any adaptation of deviating basal and postprandial blood glucose values have to occur immediately after blood glucose self-control. Consequently, algorithms have been derived from the insulin production rate of healthy man [49, 54] : basal (= fasting rate) insulin 1.0 U/h, prandial 1.35 U per 12 g carbohydrate [54] and 0.3 to 0.5 U per 100 kcal of protein/fat-mixture (Table 1) . These values may have to be adapted empirically depending on the patient's insulin sensitivity and the extent of his residual capacity for endogenous insulin release [113] .
Within the frame of this 'basis-bolus concept' [114] provision of basal insulin can be made either by a lowrate continuous infusion of regular insulin with a technical device, i. e. insulin infusion pump, or by twice daily subcutaneous injection of an appropriate conventional long-acting insulin preparation [17, 113] . To cope with prandial insulin requirement, tailored doses of regular insulin are to be superimposed either with a syringe or an infusion device.
Applying this simple strategy in combination with a fixed diet, e.g. during continuous intravenous [54] or subcutaneous insulin infusion, but without blood glucose self-control, considerable progress towards normoglycaemia has been achieved in Type 1 diabetes [115] [116] [117] . The induced improvement in actual glycaemia was, however, only maintained during hospitalization, but less so on an outpatient basis [118] . This failure is most likely due to a variety of exogenous, commonly uncontrollable factors, which include daily stress, exercise, variation of food absorption from the gut as well as of insulin from a subcutaneous injection site.
To overcome such interference with insulin action immediate correction of aberrant blood glucose values as recorded by blood glucose self-monitoring has be- come mandatory to permit near-normoglycaemic insulin substitution, which has to aim at a dynamic target (fasting and preprandially: 5.6mmol/1; l h pp: less than 8.9 mmol/1; 2 h pp: less than 6.7 mmol/1). To this end, tentative but useful algorithms (Table 1) had also to be defined [113, 119] for correction of blood glucose levels off a set target (ABG, mmol/1: 1 U regular insulin = -1.9 x 60. 'K'-t. kg body wt.-t ; 50 kcal carbohydrates = +2.8 x 60.kg body wt.-t). In this formula 'K' estimates insulin sensitivity as the ratio between the patient's actual, empirically determined daily insulin need and his theoretical insulin requirement [49] . To avoid cumulative action any correction by insulin of hyperglycaemia must not be repeated before three hours. Postponing correction of aberrant blood glucose values, however, forfeits the possible benefits of blood glucose self-control. The described technique permits the patient to fast without fear of hypoglycaemia and to adapt food intake to personal life style, which helps in recruiting motivation for long-term cooperation and has previously been attempted with simple monitoring tools in children [120] .
Among the C-peptide negative Type i diabetic patients taught the technique of near normoglycaemic insulin substitution adherence to the method was 98%, and 52% of the patients presented with normal HbA1c one year after learning to aim at near-normoglycaemia [17, 119] . Their improved metabolic control is mirrored by long-term mean weekly blood glucose values (Fig. 9 ) below the range described as impaired glucose tolerance, and mean HbAlc values at the upper limit of normal. Intermittent hypoglycaemic episodes were encountered with about the same frequency (mild, 1:6 per week; severe, 0.16 per year) as during conventional insulin treatment [121] , but somewhat less often than during continuous subcutaneous insulin infusion (CSII) [122] . Optimal compliance was achieved in insulin-dependent diabetic patients beyond puberty aged 30 + 10 (SD) years as reflected by HbAlc values close to the upper normal range [ Fig. 10] , and particularly by pregnant Type 1 diabetic patients (n = 17), all of whom delivered normal weight children at term without complications.
Outlook
Thus, returning to the questions posed initially, we have to describe conventional insulin treatment as a life-saving procedure using a fixed algorithm, which for its neglect of physiological patterns of insulin release does not hold any promise for further improvement of the metabolic fate of our patients. This can be improved by intensified insulin treatment, which employs in addition to a fixed algorithm blood glucose self-control and unsystematic blood glucose correction. Conversely, we have to conclude that functional insulin substitution using physiologic key values of insulin release and immediate systematic correction of aberrant blood glucose concentration for treatment of insulin deficieny will help the patient more successfully to aim at long-term near-normoglycaemia. Such strategy reverses that of conventional insulin treatment by not treating insulin action with a fixed diet, but hyperglycaemia with insulin. It, however, requires the attending physician to appropriately inform and train the insulin-deficient patients, as there is a close relationship (Fig. 11 ) between metabolic outcome, insulin substitution and patient training. Such education needs to be structured [123, 124] , and provides the patient with a drivers' licence for the use of insulin and for avoidance of unnecessary hypo-and hyperglycaemia.
Since no one else but the patient is the master in the health system in which all of us serve, translation of available knowledge to clinical practice is one of our most important tasks. To avoid melancholy and to be more successful we have to use information instead of coercion, or a dynamic (functional) instead of a fixed algorithm. For treatment of Type 1 diabetes this requires, instead of acute intervention, which we are taught throughout our career, continuous intervention by permanent information to permit the patients to take care of themselves as much as possible. The more carefully a Type1 diabetic patient is able to respond promptly to his individual needs, the less likely he will be assigned a final diagnosis of brittle diabetes, which is an extremely rare syndrome, whose misdiagnosis is common event [125] .
Thus, if we are to tackle the challenge of better glycaemic control in Type1 diabetes, which can be achieved by applying available knowledge, then we will have to start (1) by training the trainers [123] , and (2) by making ourselves, i.e. the physicians at large, and the affected Type 1 diabetic patients aware that much more applicable knowledge is available than used. Major obstacles to better training and thus care of Type 1 diabetic patients certainly are rotation of attending physicians, which needs to be planned carefully, and the fact that doctors are not necessarily experienced teachers, which makes it mandatory to better organize information transfer. Where this cannot be done, possibly well trained ambulatory teams available for hire would be able to fill the gap.
If this Claude Bernard lecture helped in reminding all of us of the simple, though ancient Hippocratic advice to teach, and conveyed some of the excitement of clinical investigation, then it served its purpose.
